Chengdu Shengnuo Biopharm is an API manufacturer based in China. It holds 13 active US drug master files across a filed portfolio of 13 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 8 September 2023 as VAI.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| China, China | 3006257504 |
| Molecule | Regulators | Docs |
|---|---|---|
| Bivalirudin | US FDA | 1 |
| Eptifibatide | US FDA | 1 |
| Ganirelix | US FDA | 1 |
| Icatibant | US FDA | 1 |
| Lanreotide | US FDA | 1 |
| Linaclotide | US FDA | 1 |
| Liraglutide | US FDA | 1 |
| Octreotide | US FDA | 1 |
| Retatrutide | US FDA | 1 |
| Semaglutide | US FDA | 1 |
| Teriparatide | US FDA | 1 |
| Tirzepatide | US FDA | 1 |
| Ziconotide | US FDA | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| MINSA (CR) | 1 | None |
| US FDA | None | 1 |
Choose your molecules and target markets. Chengdu Shengnuo Biopharm comes back tiered against every other supplier able to file there.
Start for free